carvedilol has been researched along with Cardiomyopathy, Chagas in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with chronic Chagas cardiomyopathy, optimization of treatment with enalapril and spironolactone and subsequent addition of carvedilol were safe and associated with benefits in cardiac function and clinical status." | 9.12 | A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. ( Botoni, FA; Dantas, JB; Ferreira, CS; Okonko, DO; Oliveira, BM; Pinto, AS; Poole-Wilson, PA; Reis, AM; Ribeiro, AL; Rocha, MO; Tavares, WC; Teixeira, AL; Teixeira, MM, 2007) |
| "In patients with chronic Chagas cardiomyopathy, optimization of treatment with enalapril and spironolactone and subsequent addition of carvedilol were safe and associated with benefits in cardiac function and clinical status." | 5.12 | A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. ( Botoni, FA; Dantas, JB; Ferreira, CS; Okonko, DO; Oliveira, BM; Pinto, AS; Poole-Wilson, PA; Reis, AM; Ribeiro, AL; Rocha, MO; Tavares, WC; Teixeira, AL; Teixeira, MM, 2007) |
| "This first update of our review found very low-quality evidence for the effects of either carvedilol or rosuvastatin, compared with placebo, for treating heart failure in people with Chagas disease." | 4.93 | Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy. ( Kwong, JS; Martí-Carvajal, AJ, 2016) |
| "This Cochrane review has found a lack of evidence on the effects of carvedilol for treating heart failure in patients with Chagas disease." | 4.88 | Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy. ( Hidalgo, R; Kwong, JS; Martí-Carvajal, AJ; Nicola, S; Simancas-Racines, D, 2012) |
| "The study population included 42 patients with Chagas cardiomyopathy and oxidative stress biomarkers were measured before and after a period of six months of treatment with carvedilol (37." | 3.78 | Carvedilol attenuates oxidative stress in chronic chagasic cardiomyopathy. ( Amara, JA; Budni, P; Dalmarco, EM; Dalmarco, JB; Frode, TS; Garlet, TR; Lino, MR; Pedrosa, RC; Simionato, EL; Wilhelm Filho, D, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martí-Carvajal, AJ | 2 |
| Kwong, JS | 2 |
| Budni, P | 1 |
| Pedrosa, RC | 1 |
| Garlet, TR | 1 |
| Dalmarco, EM | 1 |
| Dalmarco, JB | 1 |
| Lino, MR | 1 |
| Simionato, EL | 1 |
| Amara, JA | 1 |
| Frode, TS | 1 |
| Wilhelm Filho, D | 1 |
| Pimentel, Wde S | 1 |
| Ramires, FJ | 1 |
| Lanni, BM | 1 |
| Salemi, VM | 1 |
| Bilate, AM | 1 |
| Cunha-Neto, E | 1 |
| Oliveira, AM | 1 |
| Fernandes, F | 1 |
| Mady, C | 1 |
| Hidalgo, R | 1 |
| Simancas-Racines, D | 1 |
| Nicola, S | 1 |
| Botoni, FA | 1 |
| Poole-Wilson, PA | 1 |
| Ribeiro, AL | 1 |
| Okonko, DO | 1 |
| Oliveira, BM | 1 |
| Pinto, AS | 1 |
| Teixeira, MM | 1 |
| Teixeira, AL | 1 |
| Reis, AM | 1 |
| Dantas, JB | 1 |
| Ferreira, CS | 1 |
| Tavares, WC | 1 |
| Rocha, MO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy[NCT01557140] | Phase 4 | 42 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carvedilol and Cardiomyopathy, Chagas
| Article | Year |
|---|---|
Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.
Topics: Adult; Carbazoles; Cardiotonic Agents; Carvedilol; Chagas Cardiomyopathy; Heart Failure; Humans; Mid | 2016 |
Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy.
Topics: Adult; Carbazoles; Cardiotonic Agents; Carvedilol; Chagas Cardiomyopathy; Heart Failure; Humans; Pro | 2012 |
1 trial available for carvedilol and Cardiomyopathy, Chagas
| Article | Year |
|---|---|
A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Chaga | 2007 |
2 other studies available for carvedilol and Cardiomyopathy, Chagas
| Article | Year |
|---|---|
Carvedilol attenuates oxidative stress in chronic chagasic cardiomyopathy.
Topics: Adenosine Deaminase; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Antioxidants; B | 2012 |
The effect of beta-blockade on myocardial remodelling in Chagas' cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Chagas Cardiomyopathy; Collagen; Crice | 2012 |